Literature DB >> 27882127

Evaluation of the efficacy of steroid therapy on acute liver failure.

Bo Zhao1, Hui-Yan Zhang1, Gui-Juan Xie1, Hui-Min Liu1, Qing Chen1, Rui-Feng Li1, Jian-Ping You1, Sha Yang1, Qing Mao1, Xu-Qing Zhang1.   

Abstract

The effects of corticosteroids in the treatment of patients with acute or subacute liver failure (ALF or SALF) are controversial. The aims of the present study were to evaluate the efficacy of corticosteroids in improving spontaneous survival (SS) rate in patients with ALF and SALF, and to determine the groups with the highest rates of response to, and the most effective timing of, corticosteroid administration. A retrospective analysis was performed of all patients with ALF and SALF who were hospitalized in the Department of Infectious Diseases, Southwest Hospital, Chongqing, China from 2000-2012. The most common result of this was SS. A total of 238 patients were studied, including 73 patients with ALF (n=34 steroids, n=39 no steroids) and 165 patients with SALF (n=21 steroids, n=144 no steroids). Corticosteroids improved rates of SS in patients with liver failure (steroids vs. no steroids, 38.2 vs. 20.2%; P=0.011), including patients with ALF (steroids vs. no steroids, 29.4 vs. 5.1%; P=0.013) and with SALF (steroids vs. no steroids, 52.4 vs. 24.3%; P=0.013), patients with viruses (steroids vs. no steroids, 32.4 vs. 14.1%; P=0.042) and patients without viruses (steroids vs. no steroids, 50.0 vs. 24.1%; P=0.043). SS rates were extremely low for patients with coma grade 4 or Model for End-stage Liver Disease (MELD) scores ≥35 (2.2 vs. 11.8%; P=0.180). A significantly improved rate of SS associated with steroid use was observed among patients who had alanine aminotransferase (ALT) levels ≥30 × the upper limit of normal and coma grade <4 and MELD scores <35 (65.0 vs. 17.4%; P=0.002). SS associated with steroid use was significantly higher in patients with an illness duration ≤2 weeks compared with patients with an illness duration >2 weeks (51.4 vs. 15.0%; P=0.010). Corticosteroids improved the prognosis of patients with ALF and SALF. The highest rates of response were observed in patients with a lower MELD score and coma grade but who had extremely high ALT levels. The most effective treatment time was within 2 weeks of the onset of symptoms.

Entities:  

Keywords:  corticosteroids; hepatic encephalopathy; nucleoside analogues; nucleotide analogues; spontaneous survival; viral hepatitis

Year:  2016        PMID: 27882127      PMCID: PMC5103754          DOI: 10.3892/etm.2016.3720

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  30 in total

Review 1.  Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation.

Authors:  Albert J Czaja
Journal:  Liver Transpl       Date:  2007-07       Impact factor: 5.799

2.  Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B.

Authors:  Keiichi Fujiwara; Shin Yasui; Yutaka Yonemitsu; Kenichi Fukai; Makoto Arai; Fumio Imazeki; Akihiro Suzuki; Hiroshi Suzuki; Tomohito Sadahiro; Shigeto Oda; Osamu Yokosuka
Journal:  J Gastroenterol       Date:  2008-09-20       Impact factor: 7.527

3.  Long-term culture of hepatocytes: effect of hormones on enzyme activities and metabolic capacity.

Authors:  J Dich; C Vind; N Grunnet
Journal:  Hepatology       Date:  1988 Jan-Feb       Impact factor: 17.425

Review 4.  Systematic review: acute liver failure - one disease, more than 40 definitions.

Authors:  K A Wlodzimirow; S Eslami; A Abu-Hanna; M Nieuwoudt; R A F M Chamuleau
Journal:  Aliment Pharmacol Ther       Date:  2012-04-16       Impact factor: 8.171

Review 5.  Cellular and molecular mechanisms of liver injury.

Authors:  Harmeet Malhi; Gregory J Gores
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

Review 6.  Living donor liver transplantation: where do we stand and where are we going?

Authors:  Hao Lu; Ling Lu; Feng Zhang; Yuan Zhai; Xuehao Wang
Journal:  Hepatobiliary Surg Nutr       Date:  2016-04       Impact factor: 7.293

Review 7.  Acute liver failure: mechanisms of immune-mediated liver injury.

Authors:  Zeguang Wu; Meifang Han; Tao Chen; Weiming Yan; Qin Ning
Journal:  Liver Int       Date:  2010-05-20       Impact factor: 5.828

Review 8.  Advances in the management of acute liver failure.

Authors:  Da-Wei Wang; Yi-Mei Yin; Yong-Ming Yao
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

9.  Etiological investigation of fatal liver failure during the course of chronic hepatitis B in southeast China.

Authors:  Wei-Min Ke; Xue-Jun Li; Li-Na Yu; Jing Lai; Xiao-He Li; Zhi-Liang Gao; Pei-Jia Chen
Journal:  J Gastroenterol       Date:  2006-04       Impact factor: 6.772

10.  Lamivudine treatment for severe acute HBV hepatitis.

Authors:  Andrea Lisotti; Francesco Azzaroli; Federica Buonfiglioli; Marco Montagnani; Flavio Alessandrelli; Giuseppe Mazzella
Journal:  Int J Med Sci       Date:  2008-10-23       Impact factor: 3.738

View more
  9 in total

1.  Dexamethasone Transiently Enhances Transgene Expression in the Liver When Administered at Late-Phase Post Long-Term Adeno-Associated Virus Transduction.

Authors:  Zheng Chai; Xintao Zhang; Amanda Lee Dobbins; Richard Jude Samulski; Elizabeth P Merricks; Timothy C Nichols; Chengwen Li
Journal:  Hum Gene Ther       Date:  2022-01-06       Impact factor: 4.793

2.  Prednisone is not beneficial for the treatment of severe drug-induced liver injury: An observational study (STROBE compliant).

Authors:  Yue-Meng Wan; Jie-Fang Wu; Yu-Hua Li; Hua-Mei Wu; Xi-Nan Wu; Ying Xu
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

Review 3.  The Management of Glucocorticoid Therapy in Liver Failure.

Authors:  Ran Xue; Qinghua Meng
Journal:  Front Immunol       Date:  2019-10-23       Impact factor: 7.561

Review 4.  Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment.

Authors:  Fiona Marra; Elise J Smolders; Omar El-Sherif; Alison Boyle; Katherine Davidson; Andrew J Sommerville; Catia Marzolini; Marco Siccardi; David Burger; Sara Gibbons; Saye Khoo; David Back
Journal:  Drugs R D       Date:  2020-12-17

5.  Analysis of the safety of pretransplant corticosteroid therapy in patients with acute liver failure and late-onset hepatic failure in Japan.

Authors:  Takuro Hisanaga; Isao Hidaka; Isao Sakaida; Nobuaki Nakayama; Akio Ido; Naoya Kato; Yasuhiro Takikawa; Kazuaki Inoue; Masahito Shimizu; Takuya Genda; Shuji Terai; Hirohito Tsubouchi; Hajime Takikawa; Satoshi Mochida
Journal:  JGH Open       Date:  2021-03-05

Review 6.  Glucocorticoid Treatment Strategies in Liver Failure.

Authors:  Chao Ye; Wenyuan Li; Lei Li; Kaiguang Zhang
Journal:  Front Immunol       Date:  2022-03-16       Impact factor: 7.561

Review 7.  Impact of Liver Functions by Repurposed Drugs for COVID-19 Treatment.

Authors:  Rongzhi Zhang; Qiang Wang; Jianshe Yang
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

8.  Hepatitis E Infection With Acute Liver Failure.

Authors:  Timothy Phan; Christopher Desmond
Journal:  ACG Case Rep J       Date:  2020-03-18

9.  Herpes Simplex Virus-2 Hepatitis: A Case Report and Review of the Literature.

Authors:  Amna Ahmed; Alejandro Granillo; Ethan Burns; Kerri Glassner; Nishath Naseem; Christopher Force; Suzanne M Crumley; Ashley Drews
Journal:  Case Rep Med       Date:  2020-02-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.